Amgen executives didn't shed a lot of light during the company's second quarter earnings conference call on issues at the top of investors' minds: commercial expectations for PCSK9 inhibitor Repatha (evolocumab) and the strategy for growth beyond existing research and development programs.
Thousand Oaks, California-based Amgen's growth strategy has become increasingly important, since revenues from its top-selling biologic Enbrel (etanercept) are growing...
Welcome to Scrip
Create an account to read this article
Already a subscriber?